华蟾素胶囊联合GP方案对晚期非小细胞肺癌患者免疫功能的影响  

Effects of cinobufagin capsule combined with GP protocol on immune function in patients with advanced non-small cell lung cancer

作　　者：陈建英[1] 胡先全[1] 黄三雄[1] 秦连进[1] 王翔[2] 

机构地区：[1]浙江省湖州市第一人民医院普外科,浙江湖州313000 [2]浙江省湖州市第一人民医院中心实验室,浙江湖州313000

出　　处：《中国现代医生》2016年第14期12-15,共4页China Modern Doctor

基　　金：浙江省自然科学基金(LY16H160040)

摘　　要：目的探讨华蟾素胶囊联合GP方案治疗晚期非小细胞肺癌的疗效及对患者免疫功能的影响。方法选择于2013年1月~2014年1月在我院就诊的晚期非小细胞肺癌患者80例作为研究对象,分成两组,各40例。对照组:接受GP化疗方案治疗。观察组:接受GP化疗方案治疗,同时口服华蟾素胶囊治疗。结果治疗后,观察组免疫功能指标CD4^+、CD8^+、CD4^+/CD8^+水平都高于对照组,差异均有统计学意义(P<0.01或0.05)。治疗后,观察组患者的VEGF水平低于对照组,差异具有统计学意义(P<0.01)。两组主要毒副反应有恶性呕吐等胃肠道反应,骨髓抑制等,患者经对症治疗后均能耐受,没有严重的毒副反应发生,未发现华蟾素胶囊药物引起的不良反应病例(P<0.05)。随访显示,观察组患者的1年生存率和2年生存率均高于对照组,差异均有统计学意义(P<0.05)。结论华蟾素胶囊联合GP方案治疗晚期非小细胞肺癌能够提高免疫抵抗力,降低不良反应的发生率,延长患者的生存期。Objective To explore the curative efficacy of cinobufagin capsule combined with GP protocol in the treatment of advanced non-small cell lung cancer and its effects on patients＇ immune functions. Methods A total of 80 patients with advanced non-small cell lung cancer who were admitted to our hospital from January 2013 to January 2014 were selected as research subjects. They were assigned to two groups, with 40 patients in each group. Control group： GP chemotherapy protocol was given. Observation group： GP hemotherapy protocol was given, combined with oral administration of cinobufagin capsule. Results After the treatment, the immune function indicators CD4＋, CD8＋, and CD4＋/CD8＋ levels in the observation group were all higher than those in the control group, and the differences were statistically significant（P〈0.01 or 0.05）. After the treatment, VEGF level in the observation group was lower than VEGF in the control group, and the difference was statistically significant（P〈0.01 ）. The main toxic and adverse reactions in the two groups were malignant vomiting and other gastrointestinal reactions, and bone marrow inhibition. The patients were tolerant to the adverse reactions after symptomatic treatment, without severe toxic and adverse reactions. No case of adverse reactions induced by cinobufagin capsule were not detected （P〈0.05）. According to the follow-up visit, 1- year survival rate and 2-year survival rate in the observation group were both higher than those in the control group, and the differences were both statistically significant（P〈0.05）. Conclusion Cinobufagin capsule combined with GP protocol in the treatment of advanced non-small cell lung cancer is able to improve immunoresistance, reduce the inci dence rate of adverse reactions and prolong patients＇ survival time.

关 键 词：非小细胞肺癌 华蟾素胶囊 免疫功能 

分 类 号：R734.2[医药卫生—肿瘤]